---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-316043"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2025-12-11T23:59:59+00:00"
generated_at: "2026-05-16T13:31:27.286643+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Beam Therapeutics nets $255.1M cash from sale of Orbital stake in BMS acquisition

## Summary
- Beam received $255.1M in closing cash plus up to ~$26.3M from escrow for its 75M shares (17% fully diluted) of Orbital.
- Bristol-Myers Squibb completed acquisition of Orbital on December 8, 2025, triggering the payout.
- Beam to update cash runway guidance at the 2026 J.P. Morgan Healthcare Conference.

## SEC filing metadata
- accession: 0001193125-25-316043
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2025-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000119312525316043/0001193125-25-316043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000119312525316043/beam-20251208.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-316043
- JSON: https://secwatch.observer/filing/0001193125-25-316043.json
- Plain text: https://secwatch.observer/filing/0001193125-25-316043.txt

## Source-grounded claims
- claim_id: 1aee089076a679eea82cca7084e4a3d84a4b9e13
  claim: Beam Therapeutics Inc. completed a disposition involving Bristol-Myers Squibb Company for $255.1 million in closing cash consideration, plus the right to receive up to approximately $26.3 million in additional cash consideration (closed 2025-12-08).
  evidence_excerpt: of Orbital common stock, which represented a fully diluted ownership stake of approximately 17%. At the closing of the Acquisition, such shares were cancelled and converted into $255.1 million in closing cash consideration, plus the right to receive up to approximately $26.3 million in additional cash consideration upon the release, if any, of certain escrows. The
  evidence_url: https://www.sec.gov/Archives/edgar/data/1745999/000119312525316043/0001193125-25-316043-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.